INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference
August 01, 2023 08:00 ET
|
INmune Bio, Inc.
Boca Raton, FL, Aug. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s immune system to fight...
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
July 31, 2023 08:00 ET
|
INmune Bio, Inc.
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a...
INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.
July 12, 2023 08:00 ET
|
INmune Bio, Inc.
RJ Tesi MD, CEO of INmune Bio, to Present Opening Keynote on Drug Development Strategies to Improve Health Span by Treating the Chronic Diseases of Aging Boca Raton, Florida, July 12, 2023 ...
INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease
July 11, 2023 08:00 ET
|
INmune Bio, Inc.
Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months of treatment with XPro1595TM ...
INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology
July 10, 2023 16:00 ET
|
INmune Bio, Inc.
Neutralizing soluble TNF with XPro™ promotes remyelination in cuprizone model after increasing astrocyte and microglia activation responses Boca Raton, Florida, July 10, 2023 (GLOBE...
INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy
May 24, 2023 09:00 ET
|
INmune Bio, Inc.
Presidential Plenary Lecture to be Presented Wednesday, May 31 at the ICST Opening Session BOCA RATON, Fla., May 24, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announces that Mark...
INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer
May 08, 2023 08:00 ET
|
INmune Bio, Inc.
Represents First Ever Natural Killer Immunotherapy trial in Metastatic Castration-Resistant Prostate CancerWebinar at 11AM ET on Friday, May 12. BOCA RATON, Fla., May 08, 2023 (GLOBE...
INmune Bio Inc. Announces First Quarter 2023 Results and Provides Business Update
May 03, 2023 16:10 ET
|
INmune Bio, Inc.
BOCA RATON, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3
April 24, 2023 09:00 ET
|
INmune Bio, Inc.
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 24, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a...
XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease
April 19, 2023 08:30 ET
|
INmune Bio, Inc.
TNF is involved in the development of Alzheimer’s Disease pathology following traumatic brain injury and is prevented by neutralization of soluble TNF by XPRO™ Boca Raton, Florida, April 19, 2023 ...